menu
    • menu
    [{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Tenacia Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"CACNA1-T","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"}]

    Find Clinical Drug Pipeline Developments & Deals for Ulixacaltamide

    Menu

    Ulixacaltamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

                            Details : PRAX-944 (ulixacaltamide) is a highly selective small molecule inhibitor of T-type calcium channels designed for the treatment of essential tremors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 28, 2025

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

                            Details : The proceeds will complete the development of PRAX-944 (ulixacaltamide) in Phase 3 studies for essential tremor and clinical development of PRAX-628, PRAX-562, and PRAX-222 for various epilepsies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 11, 2024

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines, Inc. Announces Proposed Public Offering

                            Details : The proceeds will complete the development of PRAX-944 (ulixacaltamide) in Phase 3 studies for essential tremor and clinical development of PRAX-628, PRAX-562, and PRAX-222 for various epilepsies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 10, 2024

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Piper Sandler

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Tenacia Biotechnology

                            Deal Size : $279.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Praxis Partners with Tenacia for Ulixacaltamide in Greater China

                            Details : Tenacia will develop and commercialize PRAX-944 (ulixacaltamide), a T-type calcium channel inhibitor for essential tremor, in Greater China.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $15.0 million

                            January 05, 2024

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Tenacia Biotechnology

                            Deal Size : $279.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential T...

                            Details : Ulixacaltamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Essential Tremor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extensio...

                            Details : PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 08, 2023

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Piper Sandler

                            Deal Size : $63.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

                            Details : The net proceeds will advance the development of PRAX-944 (ulixacaltamide), a novel selective T-type calcium channel blocker, in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-562, PRAX-222 and PRAX-628 for various ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 22, 2023

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Piper Sandler

                            Deal Size : $63.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Piper Sandler

                            Deal Size : $59.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

                            Details : The net proceeds will advance the development of PRAX-944 (ulixacaltamide), a novel selective T-type calcium channel blocker, in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-562, PRAX-222 and PRAX-628 for various ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 15, 2023

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Piper Sandler

                            Deal Size : $59.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End Aft...

                            Details : PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 09, 2023

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treat...

                            Details : PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2023

                            Lead Product(s) : Ulixacaltamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth